Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast

  • US 10,092,541 B2
  • Filed: 08/13/2015
  • Issued: 10/09/2018
  • Est. Priority Date: 08/15/2014
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating a patient with stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, wherein the patient is suffering from psoriasis, the method consisting of:

  • (a) administering to the patient stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione in an initial titration dosing schedule consisting of(i) 10 mg in the morning on the first day of administration;

    (ii) 10 mg in the morning and 10 mg after noon on the second day of administration;

    (iii) 10 mg in the morning and 20 mg after noon on the third day of administration;

    (iv) 20 mg in the morning and 20 mg after noon on the fourth day of administration;

    (v) 20 mg in the morning and 30 mg after noon on the fifth day of administration; and

    (b) on the sixth and every subsequent day, administering to the patient stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione at a dose of between about 40 mg/day and about 100 mg/day.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×